Transaction · 0001532218-26-000016

Patel Sanj K

Patel Sanj K, CHAIR, CEO, reported a transaction classified as exercise at Kiniksa Pharmaceuticals International, plc involving 8609.000000 shares. Reported holdings after the transaction were 107492.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

exerciseSEC transaction code MCHAIR, CEO
KNSAKiniksa Pharmaceuticals International, plc
Trade date
Sep 01, 2026
Filing date
Sep 03, 2026
View on SEC Insider profile
Estimated value—Shares × reported price
Shares traded8.60kPrice unknown
Holdings after107kIndirect · Held by The Patel Family Irrevocable Trust of 2025
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

KNSA price since this filing

Daily closing prices, with the filing date and available return windows
KNSA · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -7.6%1w ago -0.8%1d ago -2.3%
Returns since7d -5.0%30d -5.8%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
exercise
Code M
Identifier
0001532218-26-000016
Class A Ordinary Share
Transaction date
Sep 01, 2026
Filed Sep 03, 2026, 08:48 PM · 2d delay
Shares
8,609 sh
Price unknown
Estimated value
—
Computed from shares × price
Holdings after
107,492 sh
Indirect · Held by The Patel Family Irrevocable Trust of 2025
Filing-only score

-4 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • missing_price-8 points

    price_cents is null

    Missing price reduces confidence in value-based signals.
Missing facts
  • price_cents
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CHAIRMAN & CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

  2. F2

    The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026.

  3. F3

    The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting comme…

  4. F4

    The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.

  5. F5

    The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.

  6. F6

    The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.

  7. F7

    The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.

Original filing · 0001532218-26-000016
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

KNSA